April 9, 2019 8:13am

Only the algorithms know … as expectation and probabilities are as fickle as April weather

News: ReNeuron Group (AIM: RENE) is indicating a +$54.90 or +32.11% upside on news of a partnership with Forsun Pharmaceuticals for the development, manufacture and commercialization of CTX and hRPC cell therapy programs in China.

Pre-open indications: 2 BUYs

My pre-open focus is indication analysis. An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation!

Members only. Please login.